keyword
MENU ▼
Read by QxMD icon Read
search

temozolomide

keyword
https://www.readbyqxmd.com/read/28922698/survival-improvements-with-adjuvant-therapy-in-patients-with-glioblastoma
#1
Dasantha Jayamanne, Helen Wheeler, Raymond Cook, Charles Teo, David Brazier, Geoff Schembri, Marina Kastelan, Linxin Guo, Michael F Back
BACKGROUND: Evaluate survival of patients diagnosed with glioblastoma multiforme (GBM) managed with adjuvant intensity modulated radiation therapy and temozolomide since the introduction of the European Organisation for Research and Treatment of Cancer and National Cancer Institute of Canada Clinical Trials Group (EORTC-NCIC) protocol. METHODS: All patients with GBM managed between May 2007 and December 2014 with EORTC-NCIC protocol were entered into a prospective database...
September 18, 2017: ANZ Journal of Surgery
https://www.readbyqxmd.com/read/28912531/tgf-%C3%A3-1-induced-mir-503-controls-cell-growth-and-apoptosis-by-targeting-pdcd4-in-glioblastoma-cells
#2
Pin Guo, Yanan Yu, Huanting Li, Daoxiang Zhang, Anjing Gong, Shifang Li, Wei Liu, Lei Cheng, Yongming Qiu, Weicheng Yao, Luo Li, Yugong Feng
Aberrant expression of microRNAs hae been shown to be closely associated with glioblastoma cell proliferation, apoptosis and drug resistance. However, mechanisms underlying the role of mcroRNAs in glioblastoma cell growth and apoptosis are not fully understood. In this study, we report that miR-503 is overexpressed in glioblastoma tissue compared with normal human brain tissue. Mechanistically, miR-503 can be induced by TGF-â1 at the transcriptional level by binding the smad2/3 binding elements in the promoter...
September 14, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28911239/controlled-release-of-liposome-encapsulated-temozolomide-for-brain-tumor-treatment-by-convection-enhanced-delivery
#3
Chung-Yin Lin, Rui-Jin Li, Chiung-Yin Huang, Kuo-Chen Wei, Pin-Yuan Chen
Convection-enhanced delivery (CED) is a promising technique for the delivery of drugs directly into the central nervous system (CNS) and, more specifically, the brain. CED can increase drug concentration within a brain tumor, thereby improving the therapeutic efficacy and limiting the systemic toxicity of tumoricidal agents. In this study, we evaluated a drug-liposome construct in vitro and in vivo using U87 tumor-bearing nude mice. Dipalmitoylphosphatidylcholine (DPPC)-based liposomes were designed to deliver a lipophilic temozolomide (TMZ) formulation (LipoTMZ)...
September 15, 2017: Journal of Drug Targeting
https://www.readbyqxmd.com/read/28903336/g-protein-coupled-receptor-kinase-6-is-overexpressed-in-glioma-and-promotes-glioma-cell-proliferation
#4
Li-Quan Xu, Shu-Bin Tan, Shan Huang, He-Yuan Ding, Wen-Gang Li, Yi Zhang, Shi-Qi Li, Tao Wang
The expression and potential biological functions of G protein-coupled receptor kinase 6 (GRK6) in human glioma are tested in this study. We show that protein and mRNA expression of GRK6 in human glioma tissues was significantly higher than that in the normal brain tissues. Further immunohistochemistry assay analyzing total 118 human glioma tissues showed that GRK6 over-expression was correlated with glioma pathologic grade and patients' Karnofsky performance status (KPS) score. At the molecular level, in the GRK6-low H4 glioma cells, forced over-expression of GRK6 promoted cell proliferation...
August 15, 2017: Oncotarget
https://www.readbyqxmd.com/read/28902353/identification-of-wisp1-as-a-novel-oncogene-in-glioblastoma
#5
Di Jing, Qian Zhang, Haiming Yu, Yajie Zhao, Liangfang Shen
Glioblastoma is the most common and aggressive primary brain tumor and has a high mortality in humans. However, mechanisms and factors involved in the progression of glioblastoma remain elusive. WISP1 (WNT1 inducible signaling pathway protein 1), has been suggested to be a critical regulator of cancer development. The aim of this study was to investigate the role of WISP1 in regulating the progression of glioblastoma. Clinicopathological characteristics of glioblastoma were assessed, and higher levels of WISP1 were positively associated with advanced clinical stage and a poor prognosis...
October 2017: International Journal of Oncology
https://www.readbyqxmd.com/read/28901965/anaplastic-gliomas-in-adults-an-update
#6
Cristina Izquierdo, Bastien Joubert, François Ducray
PURPOSE OF REVIEW: The current review summarizes recent advances on the oncogenesis, classification and treatment of adult anaplastic gliomas. RECENT FINDINGS: According to the 2016 WHO classification, three main molecular subgroups of adult diffuse anaplastic gliomas can be distinguished based on the 1p/19q codeletion and isocitrate dehydrogenase (IDH) mutation status. In the future, this classification may be further refined based on the telomerase reverse transcriptase promoter and alpha thalassemia/mental retardation syndrome X-linked mutation status, gene expression, DNA methylation and genomic profiling...
September 8, 2017: Current Opinion in Oncology
https://www.readbyqxmd.com/read/28901390/microrna-132-induces-temozolomide-resistance-and-promotes-the-formation-of-cancer-stem-cell-phenotypes-by-targeting-tumor-suppressor-candidate%C3%A2-3-in-glioblastoma
#7
Zhen-Xiu Cheng, Wen-Bo Yin, Zhong-Yu Wang
The prognosis of patients suffering from glioblastoma [also referred to as glioblastoma multiforme (GBM)] is dismal despite multimodal therapy. Chemotherapy with temozolomide may suppress tumor growth for a certain period of time (a few months); however, invariable tumor recurrence suggests that glioblastoma initiating cells (GICs) render these tumors persistant. Thus, the understanding of the molecular mechanisms of action of GICs as regards their role in the progression of GBM is important as such knowledge will be helpful in the discovery of novel drug targets, as well as in the design of novel therapeutic strategies for more effective treatment of the disease...
September 7, 2017: International Journal of Molecular Medicine
https://www.readbyqxmd.com/read/28900805/mgmt-and-msh6-immunoexpression-for-functioning-pituitary-macroadenomas
#8
Alexander S G Micko, Adelheid Wöhrer, Romana Höftberger, Greisa Vila, Christine Marosi, Engelbert Knosp, Stefan Wolfsberger
PURPOSE: Knowledge of biological behavior is crucial for clinical management of functioning pituitary macroadenomas. For recurrent cases unresponsive to standard treatment, temozolomide (TMZ) has been used as a therapeutic alternative. MGMT (O6-methyl-guanine-DNA methyltransferase) and MSH6 (mutS homolog 6) immunoexpression have been linked to the response to TMZ treatment and MGMT immunoexpression has been additionally linked to early recurrence of non-functioning pituitary adenomas...
September 12, 2017: Pituitary
https://www.readbyqxmd.com/read/28898169/mir-26b-reverses-temozolomide-resistance-via-targeting-wee1-in-glioma-cells
#9
Lixia Wang, Jingna Su, Zhe Zhao, Yingying Hou, Xuyuan Yin, Nana Zheng, Xiuxia Zhou, Jingzhe Yan, Jun Xia, Zhiwei Wang
Emerging evidence has demonstrated that microRNAs (miRNA) play a critical role in chemotherapy-induced epithelial-mesenchymal transition (EMT) in glioma. However, the underlying mechanism of chemotherapy-triggered EMT has not been fully understood. In the current study, we determined the role of miR-26b in regulation of EMT in stable temozolomide (TMZ)-resistant (TR) glioma cells, which have displayed mesenchymal features. Our results illustrated that miR-26b was significantly downregulated in TR cells. Moreover, ectopic expression of miR-26b by its mimics reversed the phenotype of EMT in TR cells...
September 12, 2017: Cell Cycle
https://www.readbyqxmd.com/read/28895245/genetic-evolution-of-glioblastoma-stem-like-cells-from-primary-to-recurrent-tumor
#10
Francesca Orzan, Francesca De Bacco, Giovanni Crisafulli, Serena Pellegatta, Benedetta Mussolin, Giulia Siravegna, Antonio D'Ambrosio, Paolo M Comoglio, Gaetano Finocchiaro, Carla Boccaccio
Glioblastoma (GBM) is a lethal tumor that displays remarkable genetic heterogeneity. It is also known that GBM contains a cell hierarchy driven by stem-like cells (GSCs), responsible for tumor generation, therapeutic resistance and relapse. An important and still open issue is whether phylogenetically related GSCs can be found in matched primary and recurrent GBMs, and reflect tumor genetic evolution under therapeutic pressure. To address this, we analyzed the mutational profile of GSCs isolated from either human primary GBMs (primary GSCs) or their matched tumors recurring after surgery and chemo-radiotherapy (recurrent GSCs)...
September 12, 2017: Stem Cells
https://www.readbyqxmd.com/read/28890993/chemotherapy-in-nets-when-and-how
#11
REVIEW
Anna Angelousi, Gregory Kaltsas, Anna Koumarianou, Martin O Weickert, Ashley Grossman
The majority of neuroendocrine tumours (NETs) are well-differentiated tumours that follow an indolent course, in contrast to a minority of poorly differentiated neuroendocrine carcinomas (NECs) which exhibit an aggressive course and assocaited with an overall short survival. Although surgery is the only curative treatment for NETs it is not always feasible,necessitating the application of other therapies including chemotherapy. Streptozotocin (STZ)-based regimens have long been used for advanced or metastatic well-to-moderately differentiated (G1-G2) NETs, especially those originating from the pancreas (pNETs)...
September 11, 2017: Reviews in Endocrine & Metabolic Disorders
https://www.readbyqxmd.com/read/28888050/significance-of-perivascular-tumour-cells-defined-by-cd109-expression-in-progression-of-glioma
#12
Yukihiro Shiraki, Shinji Mii, Atsushi Enomoto, Hiroyuki Momota, Yi-Peng Han, Takuya Kato, Kaori Ushida, Akira Kato, Naoya Asai, Yoshiki Murakumo, Kosuke Aoki, Hiromichi Suzuki, Fumiharu Ohka, Toshihiko Wakabayashi, Tomoki Todo, Seishi Ogawa, Atsushi Natsume, Masahide Takahashi
In the progression of glioma, tumour cells often exploit the perivascular microenvironment to promote their survival and resistance to conventional therapies. Some of these cells are considered to be brain tumour stem cells (BTSCs); however, the molecular nature of perivascular tumour cells has not been specifically clarified because of the complexity of glioma. Here, we identified CD109, a glycosylphosphatidylinositol- anchored protein and regulator of multiple signalling pathways, as a critical regulator of the progression of lower-grade glioma (World Health Organization grade II/III) by clinicopathological and whole genome sequencing analysis of tissues from human glioma...
September 9, 2017: Journal of Pathology
https://www.readbyqxmd.com/read/28887717/prognostic-importance-of-temozolomide-induced-neutropenia-in-glioblastoma-idh-wildtype-patients
#13
Taiichi Saito, Kazuhiko Sugiyama, Seiji Hama, Fumiyuki Yamasaki, Takeshi Takayasu, Ryo Nosaka, Yoshihiro Muragaki, Takakazu Kawamata, Kaoru Kurisu
Standard treatment for patients with primary glioblastoma (GBM) includes surgery, radiotherapy, and concomitant and adjuvant temozolomide (TMZ). Recent reports have demonstrated that TMZ-induced myelosuppression correlates with survival in patients with GBM. However, those results were evaluated before the 2016 revision of the World Health Organization classification. This study examined whether myelosuppression during concomitant TMZ phase correlates with prognosis in GBM, IDH-wildtype patients. We examined circulating blood cell counts in 50 patients with GBM, IDH-wildtype who received the standard treatment protocol between August 2005 and November 2015...
September 9, 2017: Neurosurgical Review
https://www.readbyqxmd.com/read/28882604/-contribution-of-temozolomide-chemotherapy-for-intramedullary-grade-ii-spinal-cord-astrocytomas-in-adults-our-experience
#14
E Chaskis, V Minichini, S Luce, D Devriendt, S Goldman, O De Witte, N Sadeghi, F Lefranc
INTRODUCTION: Grade II intramedullary astrocytomas are rare tumors. Despite a well-defined role of adjuvant temozolomide chemotherapy for brain gliomas, the contribution of this therapy for intramedullary gliomas is not yet clearly defined. METHOD: We retrospectively analyzed the data of 5 adult patients treated with temozolomide between 2008 and 2015 for a grade II intramedullary astrocytoma with progression after surgery. RESULTS: Five patients from 19 to 70 years of age (median, 37years) underwent a second surgery for the progression of a grade II intramedullary astrocytoma (median progression-free survival 26months [8-90])...
September 4, 2017: Neuro-Chirurgie
https://www.readbyqxmd.com/read/28881684/efficacy-and-safety-of-long-term-therapy-for-high-grade-glioma-with-temozolomide-a-meta-analysis
#15
Weilin Xu, Tao Li, Liansheng Gao, Jingwei Zheng, Anwen Shao, Jianmin Zhang
Further treatments are warranted in preventing recurrence or progression for high-grade glioma (HGG) patients having achieved stable disease with tolerable toxicity after the Stupp regimen (6 cycles of temozolomide). This meta-analysis aims to extensively evaluate the safety, feasibility, and efficacy of long-term therapy with temozolomide (>6 cycles) for these patients. We systematically searched the pubmed, Embase and Chinese Biomedical (CBM) databases using the strategy of combination of free-text words and MeSH terms...
August 1, 2017: Oncotarget
https://www.readbyqxmd.com/read/28881638/the-oxido-metabolic-driver-atf4-enhances-temozolamide-chemo-resistance-in-human-gliomas
#16
Daishi Chen, Manfred Rauh, Michael Buchfelder, Ilker Y Eyupoglu, Nicolai Savaskan
Malignant gliomas are devastating neoplasia with limited curative treatment options. Temozolomide (TMZ, Temcat(®), Temodal(®) or Temodar(®)) is a first-line treatment for malignant gliomas but the development of drug resistance remains a major concern. Activating transcription factor 4 (ATF4) is a critical oxido-metabolic regulator in gliomas, and its role in the pathogenesis of TMZ-resistance remains elusive. We investigated the effect of TMZ on human glioma cells under conditions of enhanced ATF4 expression (ATF4(OE)) and ATF4 knock down (ATF4(KD))...
August 1, 2017: Oncotarget
https://www.readbyqxmd.com/read/28881161/leptomeningeal-carcinomatosis-from-gastric-cancer-successfully-treated-by-the-intrathecal-methotrexate-plus-temozolomide-and-simultaneous-radiotherapy-case-report-and-literatures-review
#17
Yangyang Liu
Leptomeningeal carcinomatosis (LMC) from gastrointestinal cancer is rare. A 56-year-old man with complaint of upper abdominal pain exhibited adenocarcinoma upon histopathologic examination of biopsy specimens. At the end of adjuvant chemotherapy, the patient was affected by hearing loss. Malignant cells were observed by cerebrospinal fluid (CSF) cytology. Therefore, the patient received intrathecal methotrexate and oral temozolomide chemotherapy and radiotherapy. The progress-free survival was approximately 11 months...
September 7, 2017: Cancer Biology & Therapy
https://www.readbyqxmd.com/read/28879459/hypofractionated-radiotherapy-with-simultaneous-integrated-boost-sib-plus-temozolomide-in-good-prognosis-patients-with-glioblastoma-a-multicenter-phase-ii-study-by-the-brain-study-group-of-the-italian-association-of-radiation-oncology-airo
#18
Silvia Scoccianti, Marco Krengli, Livia Marrazzo, Stefano Maria Magrini, Beatrice Detti, Vincenzo Fusco, Luigi Pirtoli, Daniela Doino, Alba Fiorentino, Laura Masini, Daniela Greto, Michela Buglione, Giovanni Rubino, Federico Lonardi, Fernanda Migliaccio, Salvino Marzano, Riccardo Santoni, Umberto Ricardi, Lorenzo Livi
INTRODUCTION: A multicenter phase II study for assessing the efficacy and the toxicity of hypofractionated radiotherapy with SIB plus temozolomide in patients with glioblastoma was carried out by the Brain Study Group of the Italian Association of Radiation Oncology. METHODS: Twenty-four patients with newly diagnosed glioblastoma belonging to Recursive Partitioning Analysis classes III and IV were enrolled. The prescribed dose was 52.5 Gy in 15 fractions of 3.5 Gy and 67...
September 6, 2017: La Radiologia Medica
https://www.readbyqxmd.com/read/28873996/phase-i-ii-trial-of-combination-of-temozolomide-chemotherapy-and-immunotherapy-with-fusions-of-dendritic-and-glioma-cells-in-patients-with-glioblastoma
#19
Wi Jin Kim, W Christopher Newman, Nduka M Amankulor
No abstract text is available yet for this article.
July 1, 2017: Neurosurgery
https://www.readbyqxmd.com/read/28867360/the-use-of-tmz-embedded-hydrogels-for-the-treatment-of-orthotopic-human-glioma-xenografts
#20
Bandita Adhikari, Jie Li, Michael G Brandel, Diahnn Futalan, Johnny Akers, Timothy Deming, Clark C Chen, Bob S Carter
The current treatment of glioblastoma multiforme (GBM) is limited by the restricted arsenal of agents which effectively cross the blood brain barrier (BBB). For example, only a fraction of temozolomide (TMZ) administered systemically is available for therapeutic effect because of the BBB and the instability of TMZ under physiologic conditions. A novel approach to overcome this obstacle is to bypass the BBB and locally deliver chemotherapeutic agents directly to the tumor mass. We have explored the loading of TMZ into a novel hydrogel matrix, which can be delivered in liquid form and then solidifies in situ and releases chemotherapy as the matrix dissolves...
August 31, 2017: Journal of Clinical Neuroscience: Official Journal of the Neurosurgical Society of Australasia
keyword
keyword
22433
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"